ABSTRACT:
This research presents formulation, development and evaluation of novel drug delivery system for treatment of Parkinson’s disease. Parkinson’s is neurodegenerative disease caused due to degeneration of dopaminergic neurons in substantia nigra. Tremors, rigidity, bradykinesia postural instability and poor walking result from deficiency of dopamine. There is a higher risk incidence in the elderly population. Levodopa improves motor symptoms but as the disease progresses, long-term use of levodopa often leads to complications like motor fluctuations and dyskinesia. Hence objective of the study is to construct a stable and easily administered nano- formulation with enhanced bioavailability by adding levodopa into nanocochleates. The developed formulation was optimized and evaluated for particle size, zeta potential, entrapment efficacy, PXRD, DSC, TEM, in-vitro drug release, kinetic study, pharmacological activities and stability studies. Cell line study is performed to evaluate protective effect of different formulations of levodopa on H2O2 induced cytotoxicity. Animal study of optimized formulation was performed on rat model of Parkinson’s disease induced by 6-hydroxy dopamine. The test performed on developed nanocochleates demonstrated controlled drug release kinetics, indicating improved drug bioavailability and an extended duration of therapeutic impact. Therefore, research showcased a nanocochleates-based nanocarrier system that possesses enhance drug delivery controlled release, increased stability, reduced dosage, and practical uses in the field of biomedicine.
Cite this article:
Vaishali Parag Rawal*, Dr. Subodh Anil Gangurde. Formulation, Development and Evaluation of NDDS Formulation for Treatment of Parkinson’s Disease. IJRPAS, July 2025; 4 (7): 48-54.DOI: https://doi.org/https://doi.org/10.71431/IJRPAS.2025.4705
1. S. Bharath, M. Hsu, D. Kaur, S. Rajagopalan, J.K. Andersen,Glutathione,
iron and Parkinson's disease, Biochem,Pharmacol, 64 (2002),
pp. 1037-1048
2. Chaudhuri
KR, Schapira AH. Non-motor symptoms of Parkinson’s disease: dopaminergic
pathophysiology and treatment. Lancet Neurol. 2009;8(5):464–74. doi:
10.1016/S1474-4422(09)70068-7.
3.
U. Ungerstedt,6-Hydroxydopamine
induced degeneration of central monoamine neurons,Eur J Pharmacol, 5 (1968),
pp. 107-117
4. Dexter DT, Jenner P.
Parkinson disease: from pathology to molecular disease mechanisms. Free Radic
Biol Med. 2013;62:132–44. doi: 10.1016/j.freeradbiomed.2013.01.018.
5.
J.M. Shuman, P.L. De
Jager, M.B. Feany,Parkinson's disease: genetics and pathogenesis,Annu
Rev Pathol, 6 (2011), pp. 193-222
6.
Vaishali
P. Rawal,Subodh A.Gangurde Fabrication and Evaluation of Nanocochelates Loaded
Levodopa for improved efficacy .Research J. Pharm. and Tech. 18(5): May
2025:1959-1967
7. Rawal
VP, Gangurde SA. Study of Nootropic Effect of Improved Nano Formulation Version
of Levodopa in a Rat Model of Parkinson’s Disease Induced by 6-Hydroxydopamine.
International Journal of Drug Delivery Technology. 2024;14(3):1560-1565.
8. H. Xicoy, B. Wieringa, G.J.M. Martens
The SH-SY5Y cell line in Parkinson’s disease research: A systematic review Mol.
Neurodegener., vol. 12 (2017), pp. 1-11
9.
K. Slater Cytotoxicity tests for
high-throughput drug discovery Curr. Opin. Biotechnol., vol.
12 (2001), pp. 70-74
10.
D.G. Brown, H.J. Wobst Opportunities
and challenges in phenotypic screening for neurodegenerative disease research
J. Med. Chem., 63 (2020), pp. 1823-1840
11.
K. Slater Cytotoxicity tests for
high-throughput drug discovery Curr. Opin. Biotechnol., vol.
12 (2001), pp. 70-74
12.
D. Cantu, R.E. Fulton, D.A. Drechsel, M. Patel
Mitochondrial aconitase knockdown attenuates paraquat-induced dopaminergic cell
death via decreased cellular metabolism and release of iron and H2O2 Neurochem., 118 (1) (2011),
pp. 79-92, 10.1111/j.1471-4159.2011.07290.x
13. R. Soto-Otero, E. Méndez-Alvarez, A. Hermida-Ameijeiras, A.M. Muñoz-Patiño, J.L. Labandeira-Garcia,Autoxidation
and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants:
potential implication in relation to the pathogenesis of Parkinson's
disease,J Neurochem, 74 (2000), pp. 1605-1617
14.
D. Gitler, P. Dhillon, J. Shorter
Neurodegenerative disease: Models, mechanisms, and a new hope DMM Dis. Models
Mech., vol. 10 (2017), pp. 499-502
15.
T.M. Kääriäinen, M. Piltonen, B. Ossola, H. Kekki, S. Lehtonen, T. Nenonen, ,Lack
of robust protective effect of quercetin in two types of
6-hydroxydopamine-induced parkinsonian models in rats and dopaminergic cell
cultures,Brain Res, 1203 (2008), pp. 149-159
16. R. Soto-Otero, E. Méndez-Alvarez, A. Hermida-Ameijeiras, A.M. Muñoz-Patiño, J.L. Labandeira-Garcia,Autoxidation
and neurotoxicity of 6-hydroxydopamine in the presence of some antioxidants:
potential implication in relation to the pathogenesis of Parkinson's
disease,J Neurochem, 74 (2000), pp. 1605-1617